Stock Price

Intelligent Bio Solutions raised crucial capital for its fingerprint drug test, but the deal's structure sent shares tumbling amid shareholder dilution fears.

Just months after its IPO, Kandal M Venture is fighting to stay on Nasdaq. We explore the financial woes behind the stock's dramatic fall.

As Northern Trust prepares its Q4 2025 earnings call, investors seek clues on its resilience amid shifting economic tides and strategic digital pivots.

Mixed Martial Arts Group lands $3 million in funding, with Donald Trump Jr. investing, to fuel its ambitious blockchain-based fan engagement platform.

Eightco Holdings bets big on its own stock with a $125M buyback, banking on its Worldcoin treasury and a vision for AI-proof digital identity.

Chegg repurchases convertible notes at a discount, a calculated move to strengthen its finances as it pivots to the competitive skilling market.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

As 374Water pushes its waste-destroying tech to market, a new board member with deep financial expertise and a history as a long-term investor joins.

iQSTEL caps a transformational year with a NASDAQ uplist, record revenue, and a strategic pivot to Fintech and Cybersecurity, eyeing a $1B future.

Gogo has launched its anticipated 5G network for business jets, promising a new era of speed. But can its regional advantage hold against global satellite rivals?

EUDA Health's new Helixé 2.0 supplement boasts enhanced potency, nano-delivery tech, and Halal certification to capture the booming global wellness market.

Tevogen's Dr. Ryan Saadi donates over $88,000 in company stock to a UN-recognized charity, bolstering educational programs for underserved children.

Mirum raises over a quarter-billion dollars to acquire Bluejay Therapeutics, targeting a high-potential liver disease drug and signaling major growth.

The powerboat giant expands its share repurchase in a show of financial strength, betting on long-term recovery despite a soft recreational market.

Newly public AI firm Fusemachines unveils an ambitious 2026 growth plan, but faces significant financial hurdles and deep investor skepticism.

Digital ad company Viewbix is acquiring Quantum X Labs, a deep-tech firm with a key patent in quantum error correction. Is this a visionary leap or a risky gamble?

Pfizer projects lower 2026 earnings as COVID sales wane and patents expire, shifting focus to a multi-billion dollar R&D push for future growth.

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

Kodiak Sciences is raising crucial capital with a stock offering, diluting investors but fueling its late-stage retinal drugs. Is this a necessary lifeline or a red flag?

After a NYSE delisting, FOXO Technologies is betting big on healthcare acquisitions. Is this a savvy turnaround or a high-risk gamble for investors?